ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Recombinant peptides as biomarkers for tumor response to molecular targeted therapy.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Exploiting Radiation Induction of Antigens in Cancer: Targeted Drug Delivery.International journal of molecular sciences · 2022Review
- High-Throughput Approaches to the Development of Molecular Imaging Agents.Molecular imaging and biology · 2017Review
- The immunomodulatory, antitumor and antimetastatic responses of melanoma-bearing normal and alcoholic mice to sunitinib and ALT-803: a combinatorial treatment approach.Cancer immunology, immunotherapy : CII · 2016Article
- Radiation-Guided Peptide Delivery in a Mouse Model of Nasopharyngeal Carcinoma.BioMed research international · 2016Article
- Triple Negative Breast Cancer: Nanosolutions for a Big Challenge.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2015Article
- Fucoxanthin induces apoptosis in human cervical cancer cell line HeLa via PI3K/Akt pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Drug-induced amplification of nanoparticle targeting to tumors.Nano today · 2014Article
- In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Combinatorial peptide libraries: mining for cell-binding peptides.Chemical reviews · 2014Review
- High-throughput identification of putative receptors for cancer-binding peptides using biopanning and microarray analysis.Integrative biology : quantitative biosciences from nano to macro · 2013Article
- In vitro and in vivo anticancer activity of aconitine on melanoma cell line B16.Molecules (Basel, Switzerland) · 2013Article
- Landscape phages and their fusion proteins targeted to breast cancer cells.Protein engineering, design & selection : PEDS · 2012Article
- Peptide phage display as a tool for drug discovery: targeting membrane receptors.Molecules (Basel, Switzerland) · 2011Review
- Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors.Cancer research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposePhage display technology can be used to identify peptide sequences that bind rapidly and specifically to tumors responding to sunitinib therapy. These peptides may help to address problems with current methods of assessing tumor response to therapy that can be slow and have limited usage. EXPERIMENTAL
designThe peptide of interest was isolated after four rounds of biopanning in MDA-MB-231 and MCF-7 xenografted tumors. The binding location of the peptide was investigated with immunohistochemistry. Its in vivo ability to bind to breast tumors responding to therapy was determined by treating nude mice, xenografted with various tumor cell lines, with sunitinib and using near IR imaging to assess the ability of the peptide conjugated to Alexafluor-750 to bind tumors.
resultsEGEVGLG was the dominant sequence isolated from biopanning. This peptide showed increased binding relative to control groups in two cancer cell lines (MDA-MB-435 and MCF-7 human breast) responding to sunitinib treatment, whereas no elevated binding occurred in vitro when samples were incubated with tumor cells that are unresponsive to sunitinib treatment (B16 melanoma and BxPC3 pancreatic). Mice xenografted with tumors that are responsive to sunitinib therapy showed increased peptide binding when compared with untreated control. Mice bearing tumors unresponsive to sunitinib therapy showed no increased peptide binding between treated and untreated groups.
conclusionThe use of recombinant peptides to assess the pharmacodynamic response of cancer holds promise in minimizing the duration of ineffective treatment regimens in patients, potentially providing a more rapid and less invasive assessment of cancer response to systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.